Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
| The Manila Times
Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system